Tiny protein oligomers may unlock earlier diagnosis for Alzheimer's and related diseases
Researchers suggest that targeting tiny protein oligomers, which form early in the disease process, could lead to better treatments for Alzheimer's and other protein-misfolding diseases. Current clinical approaches have largely focused on larger protein clumps, which may be less effective than addressing these earlier, more damaging species.
Why it matters
Shifting the focus of medical research to early-stage protein aggregates could revolutionize the diagnosis and treatment of neurodegenerative conditions.
by Birgitte Svennevig, University of Southern Denmark
edited by Gaby Clark , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Aggregation pathways of amyloid beta (Aβ) peptides. Credit: Nature Reviews Chemistry (2026). DOI: 10.1038/s41570-026-00867-y For more than three decades, scientists have sought to combat diseases caused by protein misfolding by targeting the large protein clumps that accumulate in affected tissues. Yet, despite intensive efforts, clinical success has been limited.
Protein-misfolding diseases include many difficult-to-cure diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS and even type 2 diabetes.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in